---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-24-013804"
form_type: "8-K"
ticker: "CERO"
cik: "0001870404"
company_name: "CERO THERAPEUTICS HOLDINGS, INC."
filed_at: "2024-02-14T23:59:59+00:00"
generated_at: "2026-06-06T02:40:34.364247+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Phoenix Biotech Acquisition amends CERo merger earnout; adds 1.875M shares with closing and IND milestones

## Summary
- Amendment creates 875,000 earnout shares fully vested at closing, offsetting sponsor forfeiture.
- Adds 1,000,000 earnout shares vesting upon FDA IND application submission (regulatory milestone).
- Existing price-based earnout targets: $12.50 (500K shares) and $15.00 (500K shares) VWAP thresholds.
- Total Company Stockholders Earn-Out Consideration now 3,075,000 shares per new allocation schedule.
- Technical changes to timing and process for earnout issuance, plus HSR filing provisions.

## SEC filing metadata
- accession: 0001213900-24-013804
- form_type: 8-K
- ticker: CERO
- cik: 0001870404
- company_name: CERO THERAPEUTICS HOLDINGS, INC.
- filed_at: 2024-02-14T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1870404/000121390024013804/0001213900-24-013804-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1870404/000121390024013804/ea193537-8k425_phoenix.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-24-013804
- JSON: https://secwatch.observer/filing/0001213900-24-013804.json
- Plain text: https://secwatch.observer/filing/0001213900-24-013804.txt

## Key facts
- Material Agreements
  CERO THERAPEUTICS HOLDINGS, INC. amended Second BCA Amendment with Phoenix Biotech Acquisition Corp., PBCE Merger Sub, Inc., CERo Therapeutics, Inc. (effective 2024-02-13).
  - Action: amendment
  - Agreement: merger
  - Counterparty: Phoenix Biotech Acquisition Corp., PBCE Merger Sub, Inc., CERo Therapeutics, Inc.
  - Effective: 2024-02-13
  source text: On February 13, 2024, the parties to the Business Combination Agreement entered into Amendment No. 2 to the Business Combination Agreement (the " Second BCA Amendment ") to create two additional pools of earnout shares of common stock, par value $0.0001 per share (" Common Stock "), one pool of which will contain 875,000 shares, which will be fully vested at closing of the Business Combination and which are being issued as an offset to the agreement by Phoenix Biotech Sponsor, LLC to forfeit an offsetting number of shares, and one pool of which will contain 1,000,000 shares, which will be fully vested upon the achievement of certain regulatory milestone-based earnout targets and make certain other technical changes to the timing and process for issuance of the 1,200,000 shares of Common Stock subject to the other earn-out conditions set forth in the Business Combination Agreement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1870404/000121390024013804/0001213900-24-013804-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.